GYBYS is committed to strengthening supply chain resilience, advancing sustainable transformation, optimizing medical circulation efficiency, and fostering industrial ecosystem synergy. By seizing opportunities in industrial evolution, we strive to build a safer, greener, more efficient, and more competitive industry chain—contributing solid strength to public health and high-quality industry development.

n Our Commitments

Ø Establish a stable and reliable supply assurance network.

Ø Fortify partnership relations based on mutual benefit and win-win results.

Ø Shape an industry development landscape driven by quality improvement and upgrading.

n Our Actions

Ø Sustainable Supply Chains：GYBYS continuously expands its supply chain cooperation network around business needs and deepen supply chain operational reforms to develop a supply chain innovation ecosystem. We constantly enhance our control over the production and supply of key TCM raw materials while continuously advancing transparent, process-oriented, and lean supply chain management. Through standardized base construction, traceability technology breakthroughs, intelligent collaborative networks, and the sharing of advantageous technologies, we continuously strengthen supply chain security and enhance supply chain resilience.

Ø Supplier Management：GYBYS continuously improves its supplier access management mechanism and optimizes audit and assessment processes to control risks at the source, safeguarding the long-term safety, stability, and compliance of the supply chain. GYBYS strengthens multi-tier management processes across key areas, including supplier access, cooperation assessment, and performance management. We strictly control supplier access and continuously improve product safety and quality through measures such as quality agreements and audits. GYBYS shares its advanced quality management practices and specialized production technologies with suppliers. We ensure that every payment is made promptly and in full according to the contract cycle, alleviating the capital turnover pressure on SMEs, and responding to payment-related inquiries and feedback in a timely manner.

Ø Supply Chain Quality：GYBYS actively responds to national policies promoting standardized production of Chinese herbal medicines. We improve TCM quality from the source, advance industrial upgrading and leverage local resource endowments to drive the development of the whole-chain characteristic industries, achieving a value leap from raw materials to deep processing.

Ø Industry Development：GYBYS actively deepens industry-university-research cooperation through regular multi-dimensional technical exchanges and industry seminars, while proactively participating in industry conferences and professional forums to share practical experience. At the same time, we lead the research and formulation of multiple industry standards—leveraging our expertise to empower the standardized and high quality development of the industry.

n Our Performance

Ø In 2025, the accumulated area of Chinese medicinal material planting bases exceeded 160,000 hectares.

Ø 4,605 supplier audits have been conducted.

Ø 148 national drug standards and provincial standards led or participated by the Company and its subsidiaries during the"14th Five-Year Plan" period.

Ø Cai Zhi Lin was elected as the first chairman unit of the Municipal Medical Institution Preparation Association in the country.

Ø HWBYS and Chen Li Ji approved to establish the Guangdong Province Science and Technology Expert Workstation.

n Our Stories